Colorectal cancer (CRC) affects one in every 23 men and 25 women, making it the third most common cancer. CRC accounts for 8% of all cancer-related deaths, making it the second most common cause of death due to cancer. Standard and conventional CRC treatments include surgical expurgation for resectable CRC and radiotherapy, chemotherapy, immunotherapy, and their combinational regimen for non-resectable CRC. Despite these tactics, nearly half of patients develop incurable recurring CRC. These constraints necessitate the development of new target-specific therapeutic strategies such as targeted immune boosting therapies, non-coding RNAs based therapies, natural products, oncolytic viral therapies, have shown promising results in preclinical and clinical studies. We have tethered the entire evolutionary trends in the development of CRC treatments and have gone over the potential of new therapies and how they might be used in conjunction with conventional treatments, as well as their advantages and drawbacks as future medicines